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Abstract
Background: The high-flow nasal cannula (HFNC) delivers up to 60 l/min of humidified air/oxygen blend at a
temperature close to that of the human body. In this study, we tested whether higher temperature and flow
decrease patient comfort. In more severe patients, instead, we hypothesized that higher flow might be associated
with improved comfort.
Methods: A prospective, randomized, cross-over study was performed on 40 acute hypoxemic respiratory failure
(AHRF) patients (PaO2/FiO2 ≤ 300 + pulmonary infiltrates + exclusion of cardiogenic edema) supported by HFNC. The
primary outcome was the assessment of patient comfort during HFNC delivery at increasing flow and temperature.
Two flows (30 and 60 l/min), each combined with two temperatures (31 and 37 °C), were randomly applied for
20 min (four steps per patient), leaving clinical FiO2 unchanged. Toward the end of each step, the following were
recorded: comfort by Visual Numerical Scale ranging between 1 (extreme discomfort) and 5 (very comfortable),
together with respiratory parameters. A subgroup of more severe patients was defined by clinical FiO2 ≥ 45%.
Results: Patient comfort was reported as significantly higher during steps at the lower temperature (31 °C) in
comparison to 37 °C, with the HFNC set at both 30 and 60 l/min (p < 0.0001). Higher flow, however, was not
associated with poorer comfort.
In the subgroup of patients with clinical FiO2 ≥ 45%, both lower temperature (31 °C) and higher HFNC flow
(60 l/min) led to higher comfort (p < 0.01).
Conclusions: HFNC temperature seems to significantly impact the comfort of AHRF patients: for equal flow, lower
temperature could be more comfortable. Higher flow does not decrease patient comfort; at variance, it improves
comfort in the more severely hypoxemic patient.
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Background
The high-flow nasal cannula (HFNC) is a new non-
invasive, easy-to-use respiratory support for adult pa-
tients with acute hypoxemic respiratory failure (AHRF).
The HFNC delivers 30–60 l/min of humidified air and
oxygen blend at the desired FiO2 and temperature [1].
Several recent randomized clinical trials in patients
with or at risk for AHRF described decreased need for
invasive mechanical ventilation and improved survival
by early application of HFNC compared to standard
oxygen or non-invasive positive pressure ventilation
(NIPPV) [2, 3]. The HFNC is associated with several
beneficial physiologic effects, potentially promoting
spontaneous breathing, avoiding patient exhaustion, and
decreasing the risk of patient self-inflicted lung injury
(P-SILI) [4–8].
Although most studies reported that application of the
HFNC is associated with higher patient comfort in com-
parison to NIPPV [2, 3], none investigated the degree of
comfort at different HFNC settings. Improved comfort
might be a strong clinical endpoint per se [9, 10] and
useful to guide optimal HFNC settings, which are still
debated. Previous clinical studies used highly heteroge-
neous criteria to set flow and temperature [11–15], and
a study from our group described that physiologic effects
of HFNC in AHRF patients might be maximized by
different personalized flow rates rather than simply by
the highest value [8], but no study investigated the
effects of different temperature settings (with highest
value commonly considered as optimal).
In this collaborative project, nurses assessed comfort
during HFNC at increasing flow and temperature in
AHRF patients. Our hypothesis was that higher flow and
temperature might reduce comfort. We also planned a
subanalysis to describe whether, in the subgroup of more
severe patients clinically requiring higher inspiratory
oxygen fraction (FiO2), higher flow could result in im-
proved comfort. The rationale was that higher HFNC
flow more effectively corrects hypoxia and copes with el-
evated inspiratory effort [7, 8], potentially tampering the
neural drive and improving comfort.
Methods
Study population
Non-intubated AHRF patients admitted to the intensive
care unit (ICU) of the Fondazione IRCCS Ca′ Granda
Ospedale Maggiore Policlinico, Milan, Italy were in-
cluded. Inclusion criteria were: new/worsening respira-
tory symptoms (e.g., dyspnea) following a known clinical
insult (e.g., pneumonia) within 1 week; PaO2/FiO2 ≤ 300
despite additional oxygen as per clinical decision; and
evidence of pulmonary infiltrates on chest X-ray or
CT scan.
Exclusion criteria were: age < 18 years; tracheostomy;
hemodynamic instability (hypotension with mean arterial
pressure < 60 mmHg despite adequate volume resuscita-
tion and vasoactive drugs); AHRF only due to cardiac
failure; severe chronic obstructive pulmonary disease
(i.e., documented stage IV or patients prescribed with
home oxygen); and altered mental status.
The Fondazione IRCCS Ca′ Granda Ethical Committee
approved the study (reference 193_2017), and informed
consent was obtained from each patient according to local
regulations. Four ICU nurses (AG, FB, LM, and IA) inde-
pendently performed the enrolment, study protocol, and
data collection. Part of the data reported here has been
presented in the form of an abstract awarded with the
Nurses and Allied Healthcare Professionals Award of the
European Society of Intensive Care Medicine (ESICM
Congress, Wien, Austria, October 2017).
Demographics and clinical severity
At enrolment, the participants’ age, sex, presence of bi-
lateral infiltrates, Sepsis-related Organ Failure Assess-
ment (SOFA) score, AHRF etiology, PaO2/FiO2 ratio,
Simplified Acute Physiology Score (SAPS) II at ICU ad-
mission, and body mass index (BMI) were collected.
Continuous monitoring
Three-lead electrocardiogram, peripheral arterial oxygen
saturation, and invasive arterial pressure were monitored
during the whole study protocol.
Study protocol
Patients were nonsedated and kept in a semirecumbent
position in a calm environment. Each patient underwent,
in random order, four 20-min steps:
1. Gas flow 30 l/min and temperature 31 °C (HF30-T31).
2. Gas flow 60 l/min and temperature 31 °C (HF60-T31).
3. Gas flow 30 l/min and temperature 37 °C (HF30-T37).
4. Gas flow 60 l/min and temperature 37 °C (HF60-T37).
The HFNC was inserted through specific medium/large
nasal prongs (Fisher & Paykel Healthcare, Auckland, New
Zealand) to fit the nares size. The attending physician clin-
ically chose the FiO2 before enrolment to target peripheral
saturation of 92–98% on pulse oximetry. FiO2 was con-
tinuously measured by a dedicated system (AIRVO™ 2;
Fisher & Paykel Healthcare, Auckland, New Zealand) con-
nected to the HFNC and kept constant during all phases
by adjusting the additional oxygen wall supply. The system
can deliver airflows between 30 and 60 l/min with set
FiO2 between 0.21 and 1.0. To identify the subgroup of
more severe patients, a threshold for clinically selected
FiO2 ≥ 45% was chosen, as this represented a viable com-
promise between the need for excluding less severe
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patients (i.e., those left at FiO2 ≤ 40% by the attending phys-
ician) [16] and assuring adequate subgroup numerosity.
Measures
Toward the end of each study phase, we collected data
for oxygen saturation, FiO2, systolic and diastolic arterial
pressure, heart rate, Borg dyspnea score, respiratory rate,
and comfort score by Visual Numerical Scale (VNS)
ranging between 1 (extreme discomfort) and 5 (very
comfortable). In fact, the VNS is commonly used to
assess comfort in the clinical environment [17], and has
already been used in larger clinical studies on HFNC
(e.g., FLORALI study [2]).
Statistical analysis
The enrolment of 40 patients was planned (study
power = 0.8, α = 0.05) based on a clinically meaningful
difference of 2.0 ± 1.5 points in patient comfort between
HF30-T31 vs HF60-T37 [1]. Numerosity seemed reason-
able also to obtain sufficiently large subgroups.
Data are expressed as mean ± standard deviation or
median (interquartile range (IQR)).
Differences between variables measured during the
four study phases (HF30-T31 vs HF60-T31 vs HF30-T37
vs HF60-T37) in the whole population and in the two
FiO2 range subgroups (fixed effects) were tested by a
generalized linear mixed model (GLIMMIX) with a car-
ryover effect. Post hoc Bonferroni or Tukey multiple
comparison tests were performed. The carryover vari-
able was the combination of flow and temperature
applied in the preceding phase to exclude influence from
the random sequence.
For comparisons of baseline variables between groups
defined by a FiO2 threshold of 45%, a paired t test or
Wilcoxon’s signed rank test was used as appropriate.
Baseline categorical variables between the two subgroups
were compared by chi-square test.
The study phase associated with the highest VNS value
for comfort was indicated as “best comfort settings” for
that individual patient, while the one with the lowest
value was indicated as “worst comfort settings”.
p < 0.05 (two-tailed) was considered statistically sig-
nificant. The statistical software used was SigmaPlot 12.0
(Systat Software Inc., San Jose, CA USA) and SAS 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
Study population
Forty patients were enrolled: mean age was 57 ± 15 years
and 16 were female (40%). The clinical condition was
quite severe, with SAPS II of 36 ± 9 and median SOFA
score of 4 (IQR 4–6). Pulmonary infiltrates were bilateral
in 28 cases (70%). AHRF was of pulmonary origin in
48% and of infectious etiology in 56% of the patients.
The main characteristics of the study population are pre-
sented in Table 1.
Effects of flow and temperature on comfort in the study
population
Patient comfort was significantly higher during steps
performed at the lower temperature (HF30-T31 and
HF60-T31) in comparison with the higher temperature
(HF30-T37 and HF60-T37) (p < 0.0001 by GLIMMIX; see
Fig. 1a legend for post hoc comparisons). On the contrary,
comfort was not affected by flow values (Fig. 1a).
Effects of flow and temperature on comfort in patients
with FiO2 ≥ 45%
A comparison of baseline characteristics in the sub-
groups of patients requiring FiO2 < 45% vs FiO2 ≥ 45%
[16] is reported in Table 1. Significant baseline differ-
ences were reported for FiO2, SpO2/FiO2, respiratory
rate, and Borg score with worse values in the more
hypoxemic patients, and these might confirm accur-
ate stratification of AHRF severity by the chosen
FiO2 threshold.
In both subgroups, lower temperature (HF30-T31 and
HF60-T31 vs HF30-T37 and HF60-T37) was still associ-
ated with higher comfort, but, at variance from the
whole population and the other subgroup, higher HFNC
flow significantly improved comfort in patients with
higher FiO2 (HF60-T31 and HF60-T37 vs HF30-T31 and
HF30-T37, p < 0.001 by GLIMMIX; see figure legend for
post hoc comparisons) (Fig. 1b).
Optimum HFNC settings for patient comfort
In the whole population, on average, comfort during
HFNC was elevated in all study phases (median 3
(IQR 2–4), mean 3.2 ± 1.4); at the patient level, fair to
high comfort (i.e., ≥ 3) was always achieved in at least one
phase. Four patients (10%) reached 3 as the maximum
comfort level (two patients during HF30-T31, one patient
during HF30-T37, one patient during HF60-T31, no pa-
tient during HF60-T37), 11 (27.5%) reached a level of 4
(four patients during HF30-T31, five patients during
HF30-T37, one patient during HF60-T31, one patient dur-
ing HF60-T37), and 25 (62.5%) reached a maximum score
of 5 (nine patients during HF30-T31, nine patients during
HF30-T37, one patient during HF60-T31, six patients dur-
ing HF60-T37).
“Best comfort settings” were HF30-T31 in 15 patients
(37.5%), HF30-T37 in 15 patients (37.5%), HF60-T31 in
three patients (7.5%), and HF60-T37 in seven patients
(17.5%) (p = 0.01) (Fig. 2a). Conversely, “worse com-
fort settings” were HF30-T31 in four patients (10%),
HF60-T31 in two patients (5%), HF30-T37 in 23 pa-
tients (57.5%), and HF60-T37 in 11 patients (27.5%)
(p < 0.0001) (Fig. 2b).
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Effects of flow and temperature on vital signs and
respiratory pattern
Among the collected variables, higher flow improved
oxygenation (p < 0.0001 by GLIMMIX; see table legend
for post hoc comparisons), while higher temperature
was associated with increased heart rate (p = 0.021 by
GLIMMIX; see table legend for post hoc comparisons)
(Table 2). However, from a clinical point of view,
changes in vital signs induced by different HFNC set-
tings were only marginally relevant.
Discussion
The main findings of our study can be summarized as
follows: in AHRF patients undergoing HFNC, comfort
assessed by Visual Numeric Scale was higher at lower
temperature, regardless of flow rate; in the subgroup of







p value, FiO2 < 45%
vs FiO2 ≥ 45%
Age (years) 57 ± 15 55 ± 14 62 ± 16 0.17
Female sex, n (%) 16 (40%) 8 (33.3%) 8 (50%) 0.29
Monolateral/bilateral infiltrates, n (%) 12 (30%)/28 (70%) 8 (33%)/16 (67%) 4 (25%)/12 (75%) 0.57
SOFA score 4 (3–6) 3.5 (3–6) 4 (3–6) 0.89
Pulmonary/extrapulmonary
cause of ARDS, n (%)
19 (48%)/21 (53%) 11 (46%)/13(54%) 8 (50%)/8 (50%) 0.80
Infectious/non-infectious cause
of ARDS, n (%)
22 (56%)/18 (45%) 14 (58%)/10 (42%) 8 (50%)/8 (50%) 0.60
FiO2 40 (40–50) 40 (40–40) 50 (50–60) < 0.0001*
Respiratory rate (bpm) 22 (18–24) 20 (18–24) 24 (20–30) 0.05*
Borg scale 2 (1–3) 1 (0–3) 3 (2–4) 0.02*
Comfort 4 (3–5) 4 (3–5) 4 (3–5) 0.81
SpO2/FiO2 241 (196–249) 248 (243–250) 192 (161–199) < 0.0001*
SAPS II 36 ± 9 38 ± 8 35 ± 11 0.35
Normally distributed variables reported as mean ± standard deviation, non-normal variables reported as median (interquartile range). p values obtained by t test,
Wilcoxon rank-sum test, or chi-square test as appropriate
ARDS acute respiratory distress syndrome, FiO2 inspired oxygen fraction, SAPS Simplified Acute Physiology Score, SOFA Sepsis-related Organ Failure Assessment,
SpO2 peripheral oxygen saturation
*Data significant at p < 0.05
Fig. 1 Impact of temperature and flow on patient comfort. Values reported as median with 10°, 25°, 75°, and 90° percentiles as vertical boxes
with error bars. a Whole population, overall p < 0.0001 (GLIMMIX). Post hoc analysis: ***p < 0.001 vs HF30-T31, ###p < 0.001 vs HF60-T31. b Subgroup
analyses: grey boxes represent FiO2 < 45% subgroup, while white boxes represent FiO2 ≥ 45% subgroup. p values from GLIMMIX analysis: treatment
effect p < 0.001; FiO2 effect = 0.055; interaction = 0.035. Post hoc analysis: *p < 0.05 vs HF30-T31; **p < 0.01 vs HF30-T31; ***p < 0.001 vs HF30-T31;
#p < 0.05 vs HF60-T31; ##p < 0.01 vs HF60-T31; ###p < 0.001 vs HF60-T31; ††p < 0.01 vs FiO2 < 45% subgroup (same step). FiO2 inspired oxygen fraction,
HF30-T31 gas flow 30 l/min and temperature 31 °C, HF60-T31 gas flow 60 l/min and temperature 31 °C, HF30-T37 gas flow 30 l/min and temperature
37 °C, HF60-T37 gas flow 60 l/min and temperature 37 °C
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more severe patients (i.e., those with clinical FiO2 ≥ 45%),
both lower temperature and higher flow were associated
with improved comfort; and HFNC settings associated
with best and worst comfort presented large variability at
the individual patient level.
In humans, the alveolar membrane is a dead-ended
structure reached only by isothermal (100% relative
humidity and 44 mg/l H2O absolute humidity) and
body-warm (37 °C) air. Thus, the respiratory support re-
specting this condition the most should be associated
with increased comfort and, potentially, with decreased
unphysiologic mechanisms (e.g., inflammation, reduced
immunity, altered airway patency) [18–23]. The HFNC,
unlike cool and anhydrous conventional oxygen therapy,
can deliver to the alveoli an air–oxygen moisturized and
heated blend. In this study, we measured patient comfort
during various HFNC settings, as comfort could repre-
sent a balanced synthesis of various physiologic mecha-
nisms, potentially being a patient-level outcome per se
[9, 10]. Previous physiologic studies in patients undergo-
ing non-invasive respiratory support assessed comfort by
the same method as used in this study (i.e., VNS) [24, 25].
Comfort during non-invasive support could be particu-
larly relevant for improving tolerance. Indeed, an ongoing
Fig. 2 Best and worst comfort. Distribution of “best comfort settings” (a) and “worst comfort settings” (b) expressed as percentage of patients
reporting highest or lowest comfort value in that particular study phase (see text for detailed description). HF30-T31 gas flow 30 l/min and temperature
31 °C, HF60-T31 gas flow 60 l/min and temperature 31 °C, HF30-T37 gas flow 30 l/min and temperature 37 °C, HF60-T37 gas flow 60 l/min
and temperature 37 °C











Systolic arterial pressure (mmHg) 122 (112–136) 121 (109–135) 124 (109–138) 120 (111–135) 0.854
Diastolic arterial pressure (mmHg) 64 (59–70) 63 (56–70) 65 (53–70) 65 (60–70) 0.731
Heart rate (bpm) 88 ± 15 87 ± 15 90 ± 15‡ 89 ± 15 0.02**
SpO2 (%) 96 (94–99) 98 (96–100)
† 96 (95–99)§ 98 (96–99)†|| < 0.0001**
Respiratory rate (bpm) 22 (18–29) 22 (19–25) 23 (19–29) 23 (19–26) 0.174
Borg scale 3 (2–5) 3 (1–5) 4 (2–5) 3 (2–5) 0.557
SpO2/FiO2 238 (192–246) 240 (196–248)
† 240 (190–248)‡ 240 (196–248)* < 0.001**
FiO2 inspired oxygen fraction, GLIMMIX generalized linear mixed model, HF30-T31 gas flow 30 l/min and temperature 31 °C, HF60-T31 gas flow 60 l/min and
temperature 31 °C, HF30-T37 gas flow 30 l/min and temperature 37 °C, HF60-T37 gas flow 60 l/min and temperature 37 °C, SpO2 peripheral oxygen saturation
Post hoc comparisons: *p < 0.01 vs HF30-T31; †p < 0.001 vs HF30-T31; ‡p < 0.05 vs HF60-T31; §p < 0.001 vs HF60-T31; ||p < 0.001 vs HF30-T37
**Data significant at p < 0.05
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randomized controlled trial on a musical intervention in
ICU patients on non-invasive ventilation has comfort
evaluated by VNS as a primary endpoint [26]. Finally, a re-
cent post hoc analysis of the FLORALI study identified
poor comfort as the only predictor of intubation in patients
on HFNC within 1 h from the start, thus suggesting a link
between comfort and improved hard clinical outcomes
[27]. Interestingly, in all of these studies [1, 24, 25, 27]
dyspnea was independently assessed by the Borg scale as
we did. Relief of dyspnea is only one component of
improved comfort, and discomfort can still be present at
relatively low dyspnea scores, its determinants being wider
and more holistic (e.g., including also physiologic and
sensorial factors).
Our findings that comfort is higher at T31 than at T37
independently from the set flow rate might suggest that
a series of negative physiologic (e.g., unbalanced water
retention) and psychosomatic (e.g., excessive heating of
the nostrils) signals might prevail over the advantage of
maximum humidity. However, since during use of the
HFNC the heating and moisturizing function of the
upper airways is preserved, inspired gases at 31 °C with
full humidification should already prevent airway dry-
ness and associated lesions. Hence, starting the HFNC at
lower temperature (and eventually increasing it with
time) may be a reasonable clinical approach to exploit
the positive clinical outcomes deriving from higher toler-
ance, longer application of the non-invasive support, and
improved comfort per se.
Equally complex are the effects of flow rate on com-
fort, due to the potential interplay between mechanical,
chemical, and psychological stimuli [28, 29]. Previous
studies showed that higher HFNC flow allows a more re-
liable correspondence between set and alveolar FiO2 and
obtains higher PEEP effects [8, 14]. Our finding that, in
the whole population, comfort at lower flow did not dif-
fer significantly from higher flow might indicate either a
low patient severity (with relatively low inspiratory flow)
or a prevalence of biochemical stimuli and sensation of
airway dryness over those deriving from more effective
mechanical displacement of the respiratory system.
In more severe patients clinically requiring higher
FiO2 levels, better comfort was reached at higher flow
rates (60 l/min) and this might suggest that more effect-
ive correction of hypoxemia and/or improved lung me-
chanics [7, 8] might have prevailed at higher flow as
determinants of comfort. As a clinical reference, higher
flows could be recommended in more severe patients
requiring higher FiO2 as this could couple improved
physiology [8, 14] with higher comfort.
The finding that the “best and worst comfort” was
reached at different combinations of flow and temperature
in the individual patient might suggest that HFNC is yet
another ICU treatment that could benefit from
personalized rather than average standardized settings
[30]. AHRF is a highly heterogeneous syndrome with
regards to etiology (e.g., trauma vs infection), lung me-
chanics (higher vs lower compliance), and systemic in-
volvement (number of organ failures) [31] and it seems
physiologically sound that the same “average” treatment
should not be applied to all patients. As in the acute re-
spiratory distress syndrome, where PEEP, tidal volume,
fluid management, and extracorporeal CO2 removal might
have largely different effects based on patient subpheno-
type [32–35], HFNC settings might need to be applied in
an individualized fashion. To this end, our findings might
suggest that comfort could be the bedside endpoint to
personalize HFNC titration, but this should be validated
in larger studies.
Our study has some limitations. First, its primary aim
was to assess patient comfort, which might be viewed
only as a psychologic secondary outcome. However, pa-
tients experience a sense of relief when their physical
and psychologic comfort needs are met [9, 10], and com-
fort might be an accurate multifaceted method to esti-
mate and improve the effectiveness of non-invasive
respiratory support [24–26]. Moreover, pilot data suggest
a link between poor comfort early during application of
HFNC and subsequent intubation [27]. Second, the re-
sults derive from a short-time observation (20 min for
each phase) and they should be confirmed by more
extensive surveillance. Third, we tried to precisely define
AHRF but our population was likely highly heteroge-
neous in terms of etiology, inflammation activation, and
derangement of respiratory mechanics. Fourth, the more
severe subgroup was identified by clinically set FiO2,
which might have some individual discretion. However,
clinical FiO2 was somehow standardized to obtain ac-
ceptable SpO2 and could also reflect a more global
evaluation of the patient’s severity by the attending phys-
ician; a previous study showed high discriminatory
power of FiO2 for ARDS severity [16]; and objective as-
sessment of AHRF severity in non-intubated patients is
challenging as accepted measures such as intrapulmon-
ary shunt or respiratory system compliance are lacking.
Fifth, we did not explore midway settings but only
extremes of temperature and flow; for this reason, it is
difficult to understand whether the correlation between
comfort and temperature is linear or characterized by a
steep threshold change.
Conclusions
Set temperature during use of the HFNC seems to sig-
nificantly impact the comfort of AHRF patients: for
equal flow, lower temperature could be more comfort-
able. Higher flow does not decrease comfort: on the
contrary, in the subgroup of more severely hypoxemic
patients, higher flow improves comfort. At the individual
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patient level, high variability exists in the settings associ-
ated with highest and lowest comfort, and the HFNC
might need personalized titration. To this end, patient
comfort might already represent a smart and crafty indi-
cator to guide settings of non-invasive respiratory sup-
port by HFNC.
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